Description

NSI-189 Freebase Powder

NSI-189 Freebase
CAS Number	1270138-40-3
Molar Mass	366.509 g·mol−1
Chemical Formula	C22H30N4O
IUPAC Name	(4-Benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone

Introduction

NSI-189 Freebase is a meticulously formulated research product designed explicitly for scientific exploration, with a strict exclusion of any mention of human consumption. This freebase form of NSI-189 serves as a valuable tool for researchers delving into its unique properties and potential benefits across various research domains.

Key Characteristics

NSI-189 Freebase is a derivative of benzylpiperazine, known for its potential impact on neuroregeneration and cognitive function. As a member of the nootropic class, it has become a focus of research due to its potential pro-cognitive effects.

Research Applications

NSI-189 Freebase finds versatile applications in research domains, offering researchers a tool to explore its potential benefits. Its applications extend to investigations into major depressive disorder, pro-cognitive efficacy, and its potential role in stroke recovery.

Research Benefits

NSI-189 Freebase and Major Depressive Disorder

Studies suggest that NSI-189 Freebase may have potential applications in addressing major depressive disorder (MDD). Research in this domain aims to understand its mechanisms of action and potential therapeutic applications in the context of depressive disorders.

NSI-189 Freebase and Pro Cognitive Efficacy

Preliminary research indicates that NSI-189 Freebase may have pro-cognitive effects, potentially influencing memory and cognitive function. Investigations into its impact on cognitive enhancement contribute to understanding its potential applications in supporting cognitive processes.

NSI-189 Freebase and Stroke

Research suggests that NSI-189 Freebase may have implications for stroke recovery, potentially influencing neuroregeneration and functional recovery post-stroke. Studies exploring its effects on stroke-related conditions contribute to understanding its potential applications in neurorehabilitation.

Summary

NSI-189 Freebase, developed exclusively for research purposes, provides researchers with a unique avenue for investigating its potential benefits in major depressive disorder, pro-cognitive efficacy, and stroke recovery. The distinctive characteristics of NSI-189 Freebase make it a promising subject for further exploration in neuroscientific and neuropsychiatric research.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry. 2016 Oct;21(10):1372-80. doi: 10.1038/mp.2015.178. Epub 2015 Dec 8. Erratum in: Mol Psychiatry. 2016 Oct;21(10):1483-4. PMID: 26643541; PMCID: PMC5030464. [Read More].
2. McIntyre RS, Johe K, Rong C, Lee Y. The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects. Expert Opin Investig Drugs. 2017 Jun;26(6):767-770. doi: 10.1080/13543784.2017.1324847. Epub 2017 May 8. PMID: 28460574. [Read More].
3. Tajiri N, Quach DM, Kaneko Y, Wu S, Lee D, Lam T, Hayama KL, Hazel TG, Johe K, Wu MC, Borlongan CV. NSI-189, a small molecule with neurogenic properties, exerts behavioral, and neurostructural benefits in stroke rats. J Cell Physiol. 2017 Oct;232(10):2731-2740. doi: 10.1002/jcp.25847. Epub 2017 Apr 25. PMID: 28181668; PMCID: PMC5518191. [Read More].